Pharma Tech Outlook magazine has selected ibidi for their top 10 list of the leading virology tech solution providers in Europe. This ranking underscores that ibidi, with its set of advanced and integrated offerings, is an important partner for industrial researchers in this field.
The magazine’s annual list, determined by a panel of experts and members of Pharma Tech Outlook’s editorial board, recognizes companies that are delivering forward-thinking solutions for virology research. ibidi’s position on this list was based on an evaluation of its technical capabilities, industry expertise and recognition, market presence, and innovation.
As a leading supplier of functional cell-based assays and advanced products for cellular microscopy, ibidi provides an innovative surface technology that can be used to arrange adherent cells in regular (micro) patterns, either individually or in small groups. This enables the researcher to simultaneously visualize the influence of drugs and viruses on the cells, and then capture the exact details of the infection process. “This direct method of observation gives scientists unmatched access to valuable data,” says Dr. Roman Zantl, CEO, ibidi.
During the Corona crisis, several research groups approached ibidi with the challenge of mimicking the lung situation. To make this possible, ibidi established solutions for culturing lung epithelial cells at an air-liquid interface with simultaneous microscopy. With this technology, scientists can observe the interaction between viruses and host cells under in vivo-like conditions, then receive fast and reliable information about the mode of action and efficacy of drugs. This will help accelerate the development of effective therapies against a virus.
Also, ibidi continues to consider cardiovascular diseases and cancer. Together with its partner company MetaVi Labs, ibidi is currently involved in the field of T-cell killing assays, in an effort to develop immuno-oncological therapies faster and more effectively.
All of these important approaches have led ibidi to this prominent award. “We are very pleased to be recognized as one of the top solution providers for virology research. This is exciting to see, especially as ibidi has been enthusiastically developing technologies in this very area for exactly 20 years,” remarks Dr. Zantl, CEO, ibidi.
About Pharma Tech Outlook
Based in the USA, Pharma Tech Outlook is a monthly magazine that covers the most important and latest developments in the pharmaceutical industry. The magazine reaches out to subscribers across the world, including pharma tech leaders directly involved in virology solutions for their organizations. For more information: virology-tech-europe.pharmatechoutlook.com
The magazine’s annual list, determined by a panel of experts and members of Pharma Tech Outlook’s editorial board, recognizes companies that are delivering forward-thinking solutions for virology research. ibidi’s position on this list was based on an evaluation of its technical capabilities, industry expertise and recognition, market presence, and innovation.
As a leading supplier of functional cell-based assays and advanced products for cellular microscopy, ibidi provides an innovative surface technology that can be used to arrange adherent cells in regular (micro) patterns, either individually or in small groups. This enables the researcher to simultaneously visualize the influence of drugs and viruses on the cells, and then capture the exact details of the infection process. “This direct method of observation gives scientists unmatched access to valuable data,” says Dr. Roman Zantl, CEO, ibidi.
During the Corona crisis, several research groups approached ibidi with the challenge of mimicking the lung situation. To make this possible, ibidi established solutions for culturing lung epithelial cells at an air-liquid interface with simultaneous microscopy. With this technology, scientists can observe the interaction between viruses and host cells under in vivo-like conditions, then receive fast and reliable information about the mode of action and efficacy of drugs. This will help accelerate the development of effective therapies against a virus.
Also, ibidi continues to consider cardiovascular diseases and cancer. Together with its partner company MetaVi Labs, ibidi is currently involved in the field of T-cell killing assays, in an effort to develop immuno-oncological therapies faster and more effectively.
All of these important approaches have led ibidi to this prominent award. “We are very pleased to be recognized as one of the top solution providers for virology research. This is exciting to see, especially as ibidi has been enthusiastically developing technologies in this very area for exactly 20 years,” remarks Dr. Zantl, CEO, ibidi.
About Pharma Tech Outlook
Based in the USA, Pharma Tech Outlook is a monthly magazine that covers the most important and latest developments in the pharmaceutical industry. The magazine reaches out to subscribers across the world, including pharma tech leaders directly involved in virology solutions for their organizations. For more information: virology-tech-europe.pharmatechoutlook.com
